The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global immunoassay market size reached US$ 27.4 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 39.9 Billion by 2027, exhibiting a growth rate (CAGR) of 6.4% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Immunoassay (IA) is a technique used to measure the concentration of analytes in a solution with an antibody or an antigen as a biorecognition agent. It plays a crucial role in clinical diagnostics, pharmaceutical analysis, environmental monitoring, and security. It is widely used in research centers, hospitals, and laboratories to diagnose different diseases and improve the overall health and well-being of humans and animals. Moreover, as it is fast, simple, and cost-effective, IA is rapidly replacing conventional tests, such as high-performance liquid chromatography (HPLC) and gas chromatography (GC), for on-site analysis of food contamination.
The escalating number of individuals suffering from chronic and infectious diseases represents one of the key factors propelling the market growth. As IA offers inherent specificity, high-throughput, and high sensitivity for the analysis of biological samples, it is used in disease diagnosis, therapeutic drug monitoring, clinical pharmacokinetics, and drug discovery around the world. Moreover, automation, versatility, and the speed of analysis, along with stringent regulatory framework regarding food safety, is influencing the demand for IA in food testing. Apart from this, researchers are developing prominent immunoanalytical systems, including surface plasmon resonance (SPR)-based instruments using bioengineering, microfluidic, and biosensor technologies. These systems help in the detection of analytes and the screening of immunological components based on biomolecular interactions. Furthermore, the emerging trend of smartphone-based formats and multiplex bead assays is anticipated to drive the demand for IAs for managing health complications in real-time and enabling in vitro diagnostics.
IMARC Group provides an analysis of the key trends in each sub-segment of the global immunoassay market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on technology, product, application and end use.
Breakup by Technology:
Breakup by Product:
Breakup by Application:
Breakup by End Use:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott, Becton Dickinson and Company, BioMérieux SA, Danaher Corporation, Merck KGaA, PerkinElmer Inc, Quidel Corporation, Siemens Healthcare Pty Ltd (Siemens AG), Sysmex Corporation and Thermo Fisher Scientific.
|Base Year of the Analysis||2021|
|Segment Coverage||Technology, Product, Application, End Use, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott, Becton Dickinson and Company, BioMérieux SA, Danaher Corporation, Merck KGaA, PerkinElmer Inc, Quidel Corporation, Siemens Healthcare Pty Ltd (Siemens AG), Sysmex Corporation and Thermo Fisher Scientific|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at